English
 
Help Privacy Policy Disclaimer
  Advanced SearchBrowse
  1. View item / 
  2. Item Summary

Item

ITEM ACTIONSEXPORT
Add to Basket
  Local TagsRelease HistoryDetailsSummary

Released
Journal Article

Poly-ligand profiling differentiates trastuzumab-treated breast cancer patients according to their outcomes

MPS-Authors

Famulok,  Michael
Max Planck Fellow Chemical Biology, Center of Advanced European Studies and Research (caesar), Max Planck Society;

External Resource

https://www.nature.com/articles/s41467-018-03631-z
(Abstract)

Fulltext (restricted access)
There are currently no full texts shared for your IP range.
Fulltext (public)

s41467-018-03631-z.pdf
(Any fulltext), 2MB

Supplementary Material (public)
There is no public supplementary material available
Citation

Domenyuk, V., Gatalica, Z., Santhanam, R., Wei, X., Stark, A., Kennedy, P., et al. (2018). Poly-ligand profiling differentiates trastuzumab-treated breast cancer patients according to their outcomes. Nature Communications, 9: 1219. doi:10.1038/s41467-018-03631-z.


Cite as: https://hdl.handle.net/21.11116/0000-0003-4AF5-6
Abstract
Assessing the phenotypic diversity underlying tumour progression requires the identification of variations in the respective molecular interaction networks. Here we report proof-ofconcept for a platform called poly-ligand profiling (PLP) that surveys these system states and distinguishes breast cancer patients who did or did not derive benefit from trastuzumab. We perform tissue-SELEX on breast cancer specimens to enrich single-stranded DNA (ssDNA) libraries that preferentially interact with molecular components associated with the two clinical phenotypes. Testing of independent sample sets verifies the ability of PLP to classify trastuzumab-treated patients according to their clinical outcomes with ROC-AUC of 0.78. Standard HER2 testing of the same patients gives a ROC-AUC of 0.47. Kaplan-Meier analysis reveals a median increase in benefit from trastuzumab-containing treatments of 300 days for PLP-positive compared to PLP-negative patients. If prospectively validated, PLP may increase success rates in precision oncology and clinical trials, thus improving both patient care and drug development.